神経障害性疼痛の世界市場 - 2024～2031年

世界の神経障害性疼痛市場は、2023年に77億6,000万米ドルに達し、2031年には149億7,000万米ドルに達すると予測され、予測期間2024～2031年のCAGRは8.6%で成長すると予測されています。

神経障害性疼痛は現在、「体性感覚神経系の病変または疾患によって引き起こされる痛み」と定義されています。この改訂は、神経障害性疼痛を「末梢神経系または中枢神経系の一次的な病変、機能障害、または一過性の摂動によって開始または引き起こされる痛み」と記述していた旧定義に取って代わるものです。

世界の神経障害性疼痛市場は、神経系の損傷や機能障害によって引き起こされる神経障害性疼痛の治療法の開発と商業化に特化した、ヘルスケア産業の重要なセグメントです。この市場は現在、糖尿病やがんなどの慢性疾患の有病率の上昇、治療技術の進歩、神経障害性疼痛の根本的なメカニズムの理解促進など、いくつかの要因によって大きな成長を遂げています。これらの要因が世界の神経障害性疼痛市場拡大の原動力となっています。

市場力学：

促進要因と阻害要因

糖尿病性神経障害の有病率の増加

糖尿病性神経障害の有病率の増加は、世界の神経障害性疼痛市場の成長を大きく促進しています。市場予測期間中、この傾向は続くと予想されます。

糖尿病は神経障害性疼痛の主要な原因であるため、糖尿病患者の増加は糖尿病性神経障害の有病率の増加と直接相関しています。糖尿病性神経障害は、糖尿病に関連する最も一般的な合併症の1つです。この有病率は地理的位置や人口統計学的要因によって異なります。この増加は主に、がんや多発性硬化症などの疾患と並んで、神経障害性疼痛の主要な原因の一つである糖尿病の罹患率の増加に関連しています。

2024年2月に発表された米国国立生物工学情報センター（NCBI）の調査発表によると、糖尿病と診断された時点で、文献上の推定では患者の10％から20％が糖尿病性末梢神経障害（DPN）と同時に診断されています。しかし、長年の糖尿病患者を対象とした研究では、これらの患者におけるDPNの有病率はより高いと報告されています。5年後には約26％が末梢神経障害を発症し、この数字は10年後には41％に上昇します。文献的には、糖尿病患者の50％から66％が生涯のうちにDPNを発症するとされています。

DPNは1型糖尿病でも2型糖尿病でも起こりうりますが、その有病率は2型糖尿病患者において顕著に高く、その主な理由は糖尿病の罹病期間が長いことと、合併症の発生率が高いことです。さらに、糖尿病はシャルコー病性神経関節症の最も一般的な原因であり、その発症率は0.1～0.4％であり、すでに末梢神経障害を患っている患者の場合、この発生率は 29% にも達することがあります。これらすべての要因が、世界の神経障害性疼痛市場に需要をもたらしています。

さらに、業界の主要企業による製品の発売と承認が、この世界の神経障害性疼痛市場の成長を牽引するでしょう。例えば、2022年7月、食品医薬品局（FDA）は、糖尿病性末梢神経障害（DPN）に伴う痛みの治療に特化した、DyAnsys社が開発した経皮的電気神経刺激（PENS）システムであるFirst Reliefデバイスを承認しました。この承認は、糖尿病の一般的な合併症に苦しむ人々に対する非侵襲的疼痛管理の選択肢を大きく前進させるものです。

また、2022年1月、メドトロニックは、糖尿病性末梢神経障害（DPN）に伴う慢性疼痛の治療用に設計された充電式神経刺激装置Intellisおよび充電不要の神経刺激装置VantaのFDA承認を取得しました。この承認により、糖尿病患者の約30％が罹患している糖尿病の一般的な合併症であるDPNに苦しむ患者の治療選択肢が広がります。

さらに、個別化医療に対する需要の高まりが、世界の神経障害性疼痛市場の拡大に寄与しています。

薬の副作用

薬の副作用は、神経障害性疼痛の世界市場の成長を妨げるでしょう。神経障害性疼痛の治療には、抗けいれん薬、抗うつ薬、オピオイドなど、さまざまな薬が使われることが多いです。これらの薬剤は効果的である一方で、患者のアドヒアランスや生活の質全体に大きな影響を与える様々な副作用を伴います。

糖尿病に伴う主な合併症のひとつに糖尿病性神経障害があり、これは主に神経、特に足に伸びる神経に影響を及ぼします。この病態は高血糖の状態が長く続くことで生じ、時間の経過とともに神経線維を損傷します。

ガバペンチンやプレガバリンなどの抗けいれん薬は、神経障害性疼痛の管理のために一般的に処方されています。しかし、これらの薬剤は、患者のコンプライアンスに影響を及ぼすいくつかの副作用を引き起こす可能性があります。ガバペンチンやプレガバリンを使用している患者は、めまい、眠気、吐き気、末梢の腫れなど、さまざまな副作用を経験する可能性があります。

これらの副作用は個人によっては耐え難いものであり、服薬を中止せざるを得なくなることもあります。さらに、他の潜在的な副作用として、目のかすみや気分の変動が含まれることがあり、これは患者が治療計画を守る意欲をさらに失わせる可能性があります。

このような副作用の存在は、疼痛管理の効果に影響を与えるだけでなく、患者の生活の質を全体的に低下させる可能性があります。その結果、ヘルスケアプロバイダーは代替療法を検討したり、投与量を調整したりする必要が生じ、治療レジメンが複雑になり、医療費が増大する可能性があります。このように、上記の要因は世界の神経障害性疼痛市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 糖尿病性神経障害の罹患率の増加
  • 抑制要因
    • 薬の副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 タイプ別

• 糖尿病性神経障害
• 化学療法誘発性末梢神経障害
• 帯状疱疹後神経痛
• 三叉神経痛
• 脊柱管狭窄症
• その他

第7章 治療の種類別

• 薬物クラス
  • 抗けいれん薬
  • 三環系抗うつ薬（TCA）
  • セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）
  • オピオイド
  • カプサイシンクリーム
  • 局所麻酔薬
  • ステロイド
  • その他
• デバイス

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• AdvaCare Pharma
• Eli Lilly and Company.
• Vertex Pharmaceuticals
• Abbott
• Medtronic
• Nevro Corp.
• Grunenthal
• Teva Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.

第12章 付録

The global neuropathic pain market reached US$7.76 billion in 2023 and is expected to reach US$14.97 billion by 2031, growing at a CAGR of 8.6 % during the forecast period 2024-2031.

Neuropathic pain is now defined as "pain caused by a lesion or disease of the somatosensory nervous system" This revision replaces the older definition, which described neuropathic pain as "pain initiated or caused by a primary lesion, dysfunction, or transitory perturbation of the peripheral or central nervous system."

The global neuropathic pain market represents a crucial segment of the healthcare industry, dedicated to the development and commercialization of treatments for neuropathic pain, which is caused by damage or dysfunction in the nervous system. This market is currently experiencing significant growth driven by several factors, including the rising prevalence of chronic diseases such as diabetes and cancer, advancements in treatment technologies, and an enhanced understanding of the underlying mechanisms of neuropathic pain. These factors have driven the global neuropathic pain market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Diabetic Neuropathy

The increasing prevalence of diabetic neuropathy is significantly driving the growth of the global neuropathic pain market. It is expected to drive throughout the market forecast period.

As diabetes is a leading cause of neuropathic pain, the increasing number of diabetic patients directly correlates with a higher prevalence of diabetic neuropathy. Diabetic neuropathy is one of the most prevalent complications associated with diabetes. This prevalence can vary based on geographical location and demographic factors. This rise is primarily linked to the growing incidence of diabetes, which is one of the leading causes of neuropathic pain, alongside conditions such as cancer and multiple sclerosis.

According to the National Center for Biotechnology Information (NCBI) research publication in February 2024, at the time of diabetes diagnosis, literature estimates indicate that 10% to 20% of patients are concurrently diagnosed with diabetic peripheral neuropathy (DPN). However, studies focusing on individuals with long-standing diabetes mellitus report a higher prevalence of DPN among these patients. After five years, approximately 26% of individuals develop peripheral neuropathy, and this figure rises to 41% after ten years. Overall, the literature suggests that between 50% to 66% of individuals with diabetes will eventually develop DPN during their lifetime.

DPN can occur in both type 1 and type 2 diabetes, but its prevalence is notably higher in individuals with type 2 diabetes, primarily due to the longer duration of the disease and the higher incidence of associated comorbidities. Additionally, diabetes mellitus is recognized as the most common cause of Charcot neuroarthropathy, with an incidence rate ranging from 0.1% to 0.4%, and this rate can be as high as 29% among patients who already have peripheral neuropathy. All these factors demand the global neuropathic pain market.

Furthermore, key players in the industry product launches and approvals that would drive this global neuropathic pain market growth. For instance, in July 2022, the Food and Drug Administration (FDA) approved the First Relief device, a percutaneous electrical neurostimulation (PENS) system developed by DyAnsys, specifically for treating pain associated with diabetic peripheral neuropathy (DPN). This approval marks a significant advancement in non-invasive pain management options for individuals suffering from this common complication of diabetes.

Also, in January 2022, Medtronic plc received FDA approval for its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator, both designed for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). This approval expands treatment options for patients suffering from DPN, a common complication of diabetes that affects approximately 30% of individuals with the condition.

Moreover, the rising demand for rising demand for personalized medicine contributes to the global neuropathic pain market expansion.

Side Effects of Medications

The side effects of medications will hinder the growth of the global neuropathic pain market. The treatment of neuropathic pain often involves a variety of medications, including anticonvulsants, antidepressants, and opioids. While these medications can be effective, they are also associated with a range of side effects that can significantly impact patient adherence and overall quality of life.

One of the major complications associated with diabetes is diabetic neuropathy, which primarily affects the nerves, particularly those extending to the feet. This condition arises from prolonged high blood sugar levels, which can damage nerve fibers over time.

Anticonvulsants such as gabapentin and pregabalin are commonly prescribed for the management of neuropathic pain. However, these medications can lead to several side effects that may impact patient compliance. Patients using gabapentin and pregabalin may experience a range of adverse effects, including dizziness, drowsiness, nausea, and peripheral swelling.

These side effects can be intolerable for some individuals, leading them to discontinue the medication. Additionally, other potential side effects may include blurred vision and mood fluctuations, which can further discourage patients from adhering to their treatment plans.

The presence of these adverse reactions not only affects the effectiveness of pain management but can also diminish the overall quality of life for patients. Consequently, healthcare providers may need to explore alternative therapies or adjust dosages, which can complicate treatment regimens and increase healthcare costs. Thus, the above factors could be limiting the global neuropathic pain market's potential growth.

Segment Analysis

The global neuropathic pain market is segmented based on type, treatment type, distribution channel, and region.

Type:

The diabetic neuropathy segment is expected to dominate the global neuropathic pain market share

The diabetic neuropathy segment holds a major portion of the global neuropathic pain market share and is expected to continue to hold a significant portion of the global neuropathic pain market share during the forecast period.

Diabetic neuropathy is a significant segment within the global neuropathic pain market, characterized by nerve damage resulting from diabetes. This condition primarily affects the feet and legs, leading to various complications that can severely impact patients' quality of life. Diabetic neuropathy refers to a range of nerve disorders caused by diabetes, affecting approximately 50% to 66% of individuals with diabetes at some point in their lives. It can manifest in different forms, including peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.

The growing prevalence of obesity, often linked to sedentary lifestyles and poor dietary habits, contributes to the rising incidence of diabetes and subsequently diabetic neuropathy. In regions like the United States, where obesity rates are climbing, there is a corresponding increase in cases of diabetic neuropathy. The escalating number of diabetes cases worldwide is a primary driver for the diabetic neuropathy segment. Projections indicate that the number of adults affected by diabetes will continue to rise significantly, leading to an increased incidence of diabetic neuropathy.

Ongoing research and development efforts are leading to the introduction of novel therapeutics aimed at effectively managing diabetic neuropathy. The launch of new products specifically designed for treating diabetic nerve pain is expected to enhance global neuropathic pain market growth.

Furthermore, key players in the industry more focus on the clinical trials that would drive this segment's growth in the global neuropathic pain market. For instnace, in May 2024, Medidata, was been selected by Lexicon Pharmaceuticals, Inc. to support the advancement of the PROGRESS study, a Phase 2b clinical trial evaluating LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP). This collaboration is particularly significant as LX9211 has the potential to become the first new non-opioid medication approved for neuropathic pain in over two decades. These factors have solidified the segment's position in the global neuropathic pain market.

Geographical Analysis

North America is expected to hold a significant position in the global neuropathic pain market share

North America holds a substantial position in the global neuropathic pain market and is expected to hold most of the market share.

The increasing incidence of neuropathic pain conditions, particularly among the aging population, significantly fuels market demand. As the population ages, the prevalence of chronic diseases such as diabetes and cancer, which are known to cause neuropathic pain continues to rise. This demographic shift leads to a greater need for effective pain management solutions.

As per Abbott news in January 2023, approximately 34.2 million Americans, or 10.5% of the U.S. population, are affected by diabetes, a chronic condition characterized by high blood sugar levels. It is estimated that around 50% of adults with diabetes will develop some form of peripheral neuropathy during their lifetime. This underscores the widespread nature of this complication among diabetic patients.

The rise in diabetes cases in North America is a major contributor to the neuropathic pain market. It is projected that over 55 million adults in North America will be affected by diabetes by 2030, leading to a corresponding increase in diabetic neuropathy cases. This growing burden creates a substantial demand for effective therapeutic options.

Ongoing research and development efforts are leading to the introduction of novel therapeutics specifically designed for neuropathic pain management. Innovative drug formulations and combination therapies are being developed to target multiple pain pathways, enhancing treatment efficacy and patient outcomes.

Moreover, in this region, a major number of key players' presence, well-advanced infrastructure, government initiatives & regulatory support, investments, and product launches & approvals would propel the global neuropathic pain market. For instnace, in April 2024, in the U.S. Vertex Pharmaceuticals made significant strides in its development of suzetrigine (formerly known as VX-548), an investigational oral medication designed to treat acute and neuropathic pain. This drug represents a potential breakthrough as it could be the first new class of medicine for pain management in over 20 years, specifically targeting the NaV1.8 sodium channel, which plays a crucial role in transmitting pain signals in the nervous system.

Also, in January 2023, Abbott received FDA approval for its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a common and debilitating complication of diabetes. This approval provides an alternative treatment option for patients suffering from DPN who may not find relief from traditional methods, such as oral medications. Thus, the above factors are consolidating the region's position as a dominant force in the global neuropathic pain market.

Asia Pacific is growing at the fastest pace in the global neuropathic pain market share

Asia Pacific holds the fastest pace in the global neuropathic pain market and is expected to hold most of the market share.

The Asia-Pacific region is witnessing an increase in the prevalence of neuropathic pain, largely due to an aging population and a rise in chronic diseases such as diabetes and cancer. This surge in patient numbers creates a significant demand for effective pain management solutions. Improvements in healthcare infrastructure across Asia-Pacific nations are enhancing access to diagnosis and treatment options for neuropathic pain.

Significant investments in research and development for neuropathic pain treatments are being made by pharmaceutical companies and government organizations. For instance, R&D spending for peripheral neuropathy in the region was estimated at USD 194 million in 2022, with expectations for further increases. This focus on innovation is anticipated to yield new therapies that effectively address unmet medical needs.

The development of novel therapies, including medications and medical devices specifically designed for neuropathic pain management, is stimulating market growth. These innovations offer improved pain relief with fewer side effects, attracting both healthcare providers and patients. Ongoing technological advancements in medical devices and treatment methodologies are likely to yield more effective and less invasive options for managing neuropathic pain. This progress provides opportunities for companies to introduce innovative products that meet evolving patient needs.

The escalating incidence of diabetes in countries like India and China is a major contributor to the neuropathic pain market. Projections indicate that millions more adults will be affected by diabetes in the coming years, leading to a corresponding increase in cases of diabetic neuropathy and driving demand for therapeutic options.

Countries such as China and India are making strides in their healthcare systems, facilitating better patient care and increasing global neuropathic pain market growth potential. Furthermore, key players' strategies such as partnerships & collaborations, and product launches would drive this global neuropathic pain market growth. For instance, in February 2023, Anglo-French Drugs & Industries Ltd., based in Bengaluru, launched a new product called AFD-NP, specifically targeting the treatment of moderate to severe neuropathic pain. This product is a combination of two active ingredients: Nortriptyline (10 mg) and Pregabalin (75 mg). The launch has received approval from the Drug Control Department, indicating that it meets regulatory standards for safety and efficacy.

Also, in July 2022, in China, Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited entered into an exclusive collaboration and commercialization agreement for Novaremed's investigational drug, NRD.E1. This innovative non-opioid therapy is being developed to treat diabetes-related neuropathic pain and other neuropathic pain conditions. The agreement outlines a financial structure that allows Novaremed to potentially receive over USD 130 million in various fees, milestone payments, and royalties on net sales.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global neuropathic pain market.

Competitive Landscape

The major global players in the neuropathic pain market include Pfizer Inc., AdvaCare Pharma, Eli Lilly and Company., Vertex Pharmaceuticals, Abbott, Medtronic, Nevro Corp., Grunenthal, Teva Pharmaceuticals Inc., and Sun Pharmaceutical Industries Ltd. among others.

Key Developments

• In November 2024, Grunenthal announced that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial known as AV001. This trial is designed to evaluate the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system specifically for treating post-surgical neuropathic pain (PSNP). If the trial results are positive, they could support an extension of QUTENZA's label in the U.S. market.
• In January 2023, Neuralace Medical received FDA clearance for its innovative Axon Therapy, designed to treat chronic painful diabetic neuropathy (PDN). This approval is significant as it marks the first time a non-invasive magnetic peripheral nerve stimulation (mPNS) treatment has been authorized for PDN, offering a new approach to pain management for millions of individuals suffering from this condition.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neuropathic pain market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Diabetic Neuropathy
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects of Medications
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Diabetic Neuropathy*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Chemotherapy-Induced Peripheral Neuropathy
• 6.4. Post-Herpetic Neuralgia
• 6.5. Trigeminal Neuralgia
• 6.6. Spinal Stenosis
• 6.7. Others

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Drug Class*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Anticonvulsants
  • 7.2.4. Tricyclic Antidepressants (TCAs)
  • 7.2.5. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • 7.2.6. Opioids
  • 7.2.7. Capsaicin Cream
  • 7.2.8. Local Anesthetics
  • 7.2.9. Steroids
  • 7.2.10. Others
• 7.3. Devices

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer Inc. *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. AdvaCare Pharma
• 11.3. Eli Lilly and Company.
• 11.4. Vertex Pharmaceuticals
• 11.5. Abbott
• 11.6. Medtronic
• 11.7. Nevro Corp.
• 11.8. Grunenthal
• 11.9. Teva Pharmaceuticals Inc.
• 11.10. Sun Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us